Chardan Capital Upgraded Audentes Therapeutics (NASDAQ:BOLD)’s Rating to Buy.

On Monday, 25 February expert analysts at Chardan Capital upped Audentes Therapeutics (NASDAQ:BOLD)‘s shares rating to Buy from Neutral. BOLD’s rating change was published in an analyst note.

The stock increased 11.38% or $2.99 during the last trading session, touching $29.26.Audentes Therapeutics, Inc. is downtrending after having declined 19.28% since February 26, 2018. BOLD has 1.28 million volume or 148.14% up from normal. BOLD underperformed by 19.28% the S&P500.

Investors expect Audentes Therapeutics, Inc. (NASDAQ:BOLD)’s quarterly earnings on March, 14., Zacks reports. This year’s earnings per share analyst estimate is awaited to be $-0.92. That is 12.20 % down compareed to $-0.82 earnings per share for last year. Last quarter $-0.97 earnings per share was reported. Analysts sees -5.15 % EPS growth this quarter.

Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects.The firm is worth $1.25 billion. The firm is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy ; AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.Currently it has negative earnings. Audentes Therapeutics, Inc. has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar.

For more Audentes Therapeutics, Inc. (NASDAQ:BOLD) news released briefly go to: Nasdaq.com, Seekingalpha.com, Nasdaq.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “Smith & Nephew $3 bln spinal deal is a backbreaker – Nasdaq” released on February 11, 2019, “GE, DHR, SGMO among premarket gainers – Seeking Alpha” on February 25, 2019, “Gear4 Debuts New Chelsea Design Packs for Samsung Galaxy S10 Devices – Nasdaq” with a publish date: February 21, 2019, “Pope declares war on sexual abuse but victims feel betrayed – Nasdaq” and the last “Does a Big Earnings Miss Mean Trouble at Harley Davidson? – Nasdaq” with publication date: January 30, 2019.